Study of JNJ-89862175 for Advanced Solid Tumors
Part of Cancer clinical trials.
This trial tests a new drug called JNJ-89862175 for people with certain advanced solid tumors, including lung adenocarcinoma, kidney cancer, ovarian cancer, and uterine cancer. The goal is to see if this treatment is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancers that has spread or cannot be removed by surgery: lung adenocarcinoma, kidney cancer (clear cell or papillary), ovarian cancer (endometrioid type), or uterine cancer (endometrioid type).
- You must be able to take care of yourself and be up and about (ECOG performance status 0 or 1).
- If you are able to become pregnant or father a child, you must use effective birth control and not donate eggs or sperm during the study and for 4 months after the last dose.
- You must not have an active cancer in the brain unless it is stable and not causing symptoms.
- You must not have had a serious heart condition in the last 6 months.
- You must not have had a solid organ or stem cell transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
This early-stage trial tests a new drug called JNJ-1761981 in people with solid tumors (cancers that form in organs or tissues, excluding brain tumors) that have spread or returned after standard treatment. The study aims to find the right dose and see how well the drug works.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This trial tests a new drug, JNJ-87704916, given alone or with other treatments for people with advanced solid tumors that have stopped responding to standard therapies. It may be an option if you have a tumor that can be injected and are in good overall health.
This trial tests a new drug, JSKN022, for people with advanced solid tumors that have stopped responding to standard treatments or are not eligible for them. The goal is to see if the drug is safe and effective.
Hear when a new Advanced-stage Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.